doi: 10.1016/j.ahj.2018.08.007.
Epub 2018 Aug 24.
Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis
Affiliations
- PMID: 30227941
- DOI: 10.1016/j.ahj.2018.08.007
Item in Clipboard
Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis
Am Heart J.
2018 Dec.
Abstract
Warfarin, a vitamin K antagonist, is associated with systemic vascular calcification. We evaluated whether rivaroxaban (a direct oral factor Xa inhibitor with no interaction with vitamin K) will slow the progression in coronary plaque volumes compared with warfarin in patients with nonvalvular atrial fibrillation using coronary computed tomography angiography.
Copyright © 2018 Elsevier Inc. All rights reserved.
Similar articles
-
Apixaban versus warfarin in evaluation of progression of atherosclerotic and calcified plaques (prospective randomized trial).Am Heart J. 2019 Jun;212:129-133. doi: 10.1016/j.ahj.2019.02.014. Epub 2019 Mar 13. Am Heart J. 2019. PMID: 31002997
-
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.J Am Heart Assoc. 2016 Jun 13;5(6):e003725. doi: 10.1161/JAHA.116.003725. J Am Heart Assoc. 2016. PMID: 27412905 Free PMC article.
-
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3. Circulation. 2014. PMID: 24895454 Clinical Trial.
-
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).Circ Cardiovasc Qual Outcomes. 2017 May;10(5):e003520. doi: 10.1161/CIRCOUTCOMES.116.003520. Circ Cardiovasc Qual Outcomes. 2017. PMID: 28495674 Free PMC article. Review. No abstract available.
-
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.Thromb Haemost. 2016 Jan;115(2):257-70. doi: 10.1160/TH15-02-0181. Epub 2015 Oct 15. Thromb Haemost. 2016. PMID: 26466666 Review.
Cited by
-
The Effects of Warfarin and Direct Oral Anticoagulants on Systemic Vascular Calcification: A Review.Cells. 2021 Mar 31;10(4):773. doi: 10.3390/cells10040773. Cells. 2021. PMID: 33807457 Free PMC article. Review.
-
Atherosclerotic plaque stabilization and regression: a review of clinical evidence.Nat Rev Cardiol. 2024 Jul;21(7):487-497. doi: 10.1038/s41569-023-00979-8. Epub 2024 Jan 4. Nat Rev Cardiol. 2024. PMID: 38177454 Review.
-
Influence of rivaroxaban compared to vitamin K antagonist treatment upon development of cardiovascular calcification in patients with atrial fibrillation and/or pulmonary embolism.Clin Cardiol. 2022 Apr;45(4):352-358. doi: 10.1002/clc.23819. Epub 2022 Mar 25. Clin Cardiol. 2022. PMID: 35332571 Free PMC article. Clinical Trial.
-
Warfarin involvement, in comparison to NOACs, in the development of systemic atherosclerosis.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 May;166(2):150-154. doi: 10.5507/bp.2022.008. Epub 2022 Feb 18. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022. PMID: 35228757 Review.
-
A review of serial coronary computed tomography angiography (CTA) to assess plaque progression and therapeutic effect of anti-atherosclerotic drugs.Int J Cardiovasc Imaging. 2020 Dec;36(12):2305-2317. doi: 10.1007/s10554-020-01793-w. Epub 2020 Feb 19. Int J Cardiovasc Imaging. 2020. PMID: 32076919 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
